Delivery Order SPE2DB22D3011-SPE2DB24FQ3DF

Award Date 8/12/24
Potential Completion Date 8/13/24
Potential Value $18K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $17,331.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for XIFAXAN 550 MG TABLET 60S, a medication used for various medical conditions. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award, valued at $35,854.87, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order for the supply of XIFAXAN 550 MG TABLET 60S, a prescription medication. The contract is a firm fixed-price delivery order with an ultimate completion date of April 30, 2025. It is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor...
This federal contract award, valued at $23,598.71, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This federal contract award, valued at $28,744.83, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of XIFAXAN 550 MG TABLET 60S, a prescription medication, with a completion date of January 22, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $88,410.13, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of February 7, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at...
This federal contract award, valued at $8,145.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a medication, with a performance period extending through April 2025. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,858.31, is for the delivery of XIFAXAN 550 MG TABLET UD 60S, a pharmaceutical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,734.40 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,173.36 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award, valued at $6,730.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of XIFAXAN 550 MG TABLET 60S, a medication used for the treatment of various medical conditions. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB24FQ3DF
    Delivery Order

This federal contract award, valued at $18,480.28, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of XIFAXAN 550 MG TABLET 60S. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 between Amerisourcebergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. This contract award does not have a set-aside designation and is expected to be completed by August 13, 2024.

Generated 11/11/24, 9:19 AM